NervGen Pharma Company Description
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study.
NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
The company was incorporated in 2017 and is based in Vancouver, Canada.
Contact Details
Address: 112-970 Burrard Street Vancouver, British Columbia V6Z 2R4 Canada | |
| Phone | 778-731-1711 |
| Website | nervgen.com |
Stock Details
| Ticker Symbol | NGENF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA64082X2032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adam H. Rogers M.D. | Chairman and Interim Chief Executive Officer |
| William Joseph Radvak BASc | Co-Founder and Advisor |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder and Independent Director |
| William J. Adams C.A., CPA, CA, CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Randall E. Kaye M.D. | Chief Medical Advisor and Director |
| Brian McAlister | Co-Founder and Advisor |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations |
| Kevin M. Rooney | Senior Vice President of Corporate Development and Strategy |
| Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management |